文献速递乳腺癌放疗

自身免疫性疾病患者保乳治疗:活动性疾病与大分割放疗对急性和晚期毒性的作用

Breast Conservation in Women with Autoimmune Disease: The Role of Active Autoimmune Disease and Hypofractionation on Acute and Late Toxicity in a Case-Controlled Series.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-03

该病例对照系列纳入2012至2016年接受保乳治疗的91例自身免疫性疾病患者,按年龄、放疗野和分割方式匹配无自身免疫性疾病的对照。大分割放疗者急性和晚期2/3级毒性无差异。

要点

  • 自身免疫病患者保乳放疗后2/3级晚期毒性显著高于对照。
  • 放疗时活动性自身免疫病与更高的2/3级晚期毒性相关。
  • 大分割放疗者急性和晚期2/3级毒性与对照无差异。

核心结论

  • 自身免疫性结缔组织病患者保乳放疗的放射性毒性发生率低,医生评定的美容效果良好至优秀。
  • 病例组晚期毒性增加,尤其是放疗时存在活动性自身免疫病的患者;大分割放疗未增加急性和晚期毒性。

研究设计与样本

  • 匹配病例对照系列,从2012至2016年1983例保乳治疗患者中识别91例自身免疫病患者,按年龄、放疗野和分割方式匹配无自身免疫病的对照。

主要发现

  • 大分割放疗者急性和晚期2/3级毒性在病例组与对照组间无差异(急性13.1% vs 11.5%,P>0.9;晚期11.9% vs 13.1%,P>0.9)。

临床怎么用

  • 自身免疫病患者接受保乳放疗时,应关注放疗时疾病活动状态对晚期毒性的影响。
  • 大分割放疗在自身免疫病患者中未显示急性和晚期毒性增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Autoimmune connective tissue disease (CTD) has historically represented a relative contraindication to breast conservation (BC) among patients with early-stage breast cancer. Controversy exists regarding the use of hypofractionated radiation therapy (RT) among patients with CTDs. We evaluated acute and late toxicity in patients with breast cancer and CTD treated with BC. METHODS AND MATERIALS: Of 1983 patients treated with BC from 2012 to 2016, we identified 91 patients with an autoimmune disease (AD). Each patient was matched to a control without AD based on age, RT field, and fractionation. RT toxicity and clinician-rated cosmesis were compared between cases and controls. Overall survival, disease-free survival, and local recurrence-free survival were estimated using the Kaplan-Meier method. RESULTS: The median follow-up was 49.9 months for cases and 53.0 months for controls, and 67% of cases and controls were treated with hypofractionated RT. There was no difference in grade 2/3 acute toxicity between cases and controls (26.4% vs. 16.5%, respectively; P = .148). There was a significantly higher rate of grade 2/3 late toxicity among cases (25.8% vs 12.1% among controls; P = .049). Active AD at the time of RT increased the rate of grade 2/3 late toxicity compared with controls (41.7% in cases vs. 11.4% in controls; P = .018). Among patients treated with hypofractionated RT, there was no difference in acute or late grade 2/3 toxicity between cases and controls (acute: 13.1% in cases vs. 11.5% in controls [P > 0.9]; late: 11.9% in cases vs. 13.1% in controls [P > 0.9]). The rates of good/excellent clinician-rated cosmesis were similar between groups (92.9% in cases vs. 98.9% in controls; P = .142). CONCLUSIONS: In the largest matched case-control study of patients with CTD treated with conventional and hypofractionated RT, we demonstrate low rates of radiation toxicity, with good to excellent clinician-rated cosmesis. There was increased late toxicity in cases, especially in patients with active AD at time of RT. There was no increase in acute or late toxicity in the patients treated with hypofractionation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Purswani JM, Oh C, Jaros B, et al. Breast Conservation in Women with Autoimmune Disease: The Role of Active Autoimmune Disease and Hypofractionation on Acute and Late Toxicity in a Case-Controlled Series. Int J Radiat Oncol Biol Phys. 2021. PMID: 33545303. doi:10.1016/j.ijrobp.2021.01.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。